Austrian firm expands in Germany
The international laboratory group Futurelab Holding GmbH has moved into the German laboratory market following its recent acquisition of Medizinisches Versorgungszentrum (MVZ) 'Labor Dr Tiller&Kollegen'. Futurelab has a registered base in Vienna and is one of the largest suppliers of private medical laboratory services in central and east Europe (EEC countries).
Founded two decades ago in Munich, the medical and diagnostic laboratory MVZ ‘Labor Dr. Tiller & Kollegen’ is one of the biggest laboratories in Bavaria. Around 250 employees analyze ca. 6,000 to 7,000 patient samples daily, received from practitioners and hospitals. In Germany it is one of the most important laboratories for special analytical procedures. Besides routine diagnostics, it also focuses on immunology, toxicology and molecular diagnostics.
Futurelab reports that it plans to develop MVZ ‘Labor Dr. Tiller&Kollegen’ as one of its competence centres for special analytical procedures in Europe, thus creating a number of additional workplaces.
Dr Friedrich-Wilhelm Tiller MD, Medical Director of MVZ commented: ‘Many years of extremely professional co-operation bonds us with Futurelab, so the integration of MVW into the Futurelab Group is a logical consequence, ensuring the continuation of our success on the international laboratory market.’
Futurelab currently employs about 2,000 people at 120 locations in Germany, Austria, Romania, Switzerland, Slovak Republic, Czech Republic, and Hungary. The company runs hospital and extramural laboratories, maintaining high-level medical laboratory diagnostics through a structurally standardised data processing network. Every day about 30,000 patient samples are run through 200,000 laboratory analysis procedures. Particularly in the area of special analysis, e.g. genetic and immunologic assays, the daily number of samples determines the quality of results, the company points out. ‘Large-scale study series guarantee a better quality of results.’
In Austria, the Slovak Republic, the Czech Republic and Hungary, the laboratory group already leads the market. In Switzerland the group counts among the top three.
Professor Michael Havel, CEO of Futurelab, said: ‘With the majority holding in MVZ ‘Labor Dr. Tiller&Kollegen’ we expect to
continue driving our successful European expansion in Germany as well. Talks are already under way with a number of medical laboratories in Germany with a view to acquisition.
Incorporating all the acquisitions to date in 2007, Futurelab’s consolidated annual turnover for 2007 is expected to be about ?140 million.
16.11.2007
